A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

NCT ID: NCT00812799

Last Updated: 2010-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

374 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients between 18 and 60 years will be randomized to receive either Oralgen grass pollen or placebo administered sublingually once a day. Treatment will start at least 16 weeks prior to the anticipated start of the pollen season 2009 and will last until the end of the pollen season 2011. Study medication will be titrated during the first period of treatment until maintenance dose has been reached.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinoconjunctivitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

randomised double-blind placebo-controlled efficacy and safety Oralgen® Grass Pollen allergic rhinoconjunctivitis allergy rhinoconjunctivitis immunotherapy grass pollen extract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Grass pollen extract

Subjects will receive 19.000 BU grass pollen extract daily sublingually

Group Type ACTIVE_COMPARATOR

Oralgen

Intervention Type DRUG

19.000 BU daily

Placebo control

Subjects will receive matching placebo control daily sublingually

Group Type PLACEBO_COMPARATOR

placebo control

Intervention Type OTHER

placebo control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oralgen

19.000 BU daily

Intervention Type DRUG

placebo control

placebo control

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Grass pollen extract

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female
* grass pollen related rhinoconjunctivitis symptoms for at least the last 2 pollen seasons
* positive skin prick test RRTSS greater or equal to 12 during the 2008 season
* signed informed consent

Exclusion Criteria

* positive skin prick test for other environmental allergens and suffering from serious allergic symptoms
* clinical history of significant symptomatic allergic rhinitis due to tree/weed pollen which potentially overlap the grass pollen season
* clinical history of symptomatic perennial allergic rhinitis caused by an allergen to which the patient is regularly exposed
* lacking of good health
* abnormal spirometry
* lower respiratory tract infection
* asthma requiring treatment other than beta-2 agonists
* oral steroids within 12 weeks before screening
* regular contraindications for use of immunotherapy
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Artu Biologicals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Artu Biologicals Europe B.V.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Folkert Roossien

Role: STUDY_DIRECTOR

Artu-Biologicals Europe B.V.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AZ St Jan, Campus Sint-Jan

Bruges, , Belgium

Site Status

Clinique Saint Luc

Brussels, , Belgium

Site Status

U.Z. St Raphael

Leuven, , Belgium

Site Status

University Hospital Leuven

Leuven, , Belgium

Site Status

CHR de la Citadelle

Liège, , Belgium

Site Status

Clinique UCL de Mont-Godinne

Yvoir, , Belgium

Site Status

Groupe Hospitalier Pellegrin

Bordeaux, , France

Site Status

Gael Taburet

Brest, , France

Site Status

Francois Durand Perdriel

Nantes, , France

Site Status

Francois Wessel

Nantes, , France

Site Status

Michel Anton

Nantes, , France

Site Status

Françoise Sanquer

Quimper, , France

Site Status

Bruno Lebeaupin

Rezé, , France

Site Status

CHRU de Strasbourg

Strasbourg, , France

Site Status

Mathieu Larrousse

Toulon, , France

Site Status

Allergie-Centrum-Charité

Berlin, , Germany

Site Status

Berufsgen. kliniken Bergmannsheil

Bochum, , Germany

Site Status

Universitätsklinik Bonn

Bonn, , Germany

Site Status

Uniklinikum Carl Gustav Carus

Dresden, , Germany

Site Status

Uniklinikum Frankfurt

Frankfurt am Main, , Germany

Site Status

MedicoKIT

Goch, , Germany

Site Status

Universitätsklinikum Halle (Saale)

Halle, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein

Lübeck, , Germany

Site Status

Klinikum der Universität München

München, , Germany

Site Status

Universitätsklinikum Münster

Münster, , Germany

Site Status

Rijnland Ziekenhuis, Location Alphen - Poli KNO

Alphen aan den Rijn, , Netherlands

Site Status

Wilhelmina ziekenhuis

Assen, , Netherlands

Site Status

Ampha De Bilt

De Bilt, , Netherlands

Site Status

Catharina Ziekenhuis

Eindhoven, , Netherlands

Site Status

AMPHA Nijmegen

Nijmegen, , Netherlands

Site Status

Sint Elisabeth Ziekenhuis

Tilburg, , Netherlands

Site Status

Prywatna Praktyka Lekarska, Gabinet Pediatryczno Alergologiczny

Bialystok, , Poland

Site Status

SP-ZOZ Osrodek Zdrowia w Bienkowce

Bieńkówka, , Poland

Site Status

SPZOZ Wojewodzki Szpital Kliniczny im.Dr.J.Biziela

Bydgoszcz, , Poland

Site Status

Slaskie Centrum Osteoporozy

Katowice, , Poland

Site Status

SP ZOZ Uniwersytecki Szpital Kliniczny Nr 1

Lodz, , Poland

Site Status

NZOZ Centrum Alergologii Prof. Buczylko

Lodz, , Poland

Site Status

SPZOZ Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego

Lublin, , Poland

Site Status

Centrum Alergologii Teresa Hofman

Poznan, , Poland

Site Status

NZOZ Lekarze Specjalisci

Wroclaw, , Poland

Site Status

Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko Slaskiego Uniwersytetu Medycznego w Katowicach

Zabrze, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny nr 3

Zabrze, , Poland

Site Status

The Alverton Practice

Penzance, Cornwall, United Kingdom

Site Status

Saltash Health Centre

Saltash, Cornwall, United Kingdom

Site Status

Cape Cornwall Surgery

St Just, Cornwall, United Kingdom

Site Status

Fowey River Practice

Fowey, Cornwal, United Kingdom

Site Status

Sea Road Surgery

Bexhill-on-Sea, Past Sussex, United Kingdom

Site Status

Atherstone Surgery

Atherstone, Warwickshire, United Kingdom

Site Status

The Porch Surgery

Corsham, Wiltshire, United Kingdom

Site Status

Layton Medical Centre

Blackpool, Lancashire, , United Kingdom

Site Status

Brighton General Hospital

Brighton, , United Kingdom

Site Status

Hathaway Medical Centre

Chippenham, , United Kingdom

Site Status

House Surgery

Crownhill, Plymouth, , United Kingdom

Site Status

Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust

London, , United Kingdom

Site Status

St. Mary's Hospital

London, , United Kingdom

Site Status

Royal National Throat, Nose & Ear Hospital

London, , United Kingdom

Site Status

QMC Notthingham, Nottingham University Hospitals NHS Trust

Nottingham, , United Kingdom

Site Status

Brannel Surgery

Saint Stephen, Saint Austell, , United Kingdom

Site Status

Northern General Hospital

Sheffield, , United Kingdom

Site Status

Avenue Surgery

Warminster, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium France Germany Netherlands Poland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AB0801

Identifier Type: -

Identifier Source: org_study_id